Irreversible End‐Stage Cardiomyopathy Following a Single Dose of Cyclophosphamide

Dadfarmay, Sina; Berkowitz, Robert; Kim, Bernard

doi:10.1111/j.1751-7133.2011.00279.x

Cited by 5 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 It was suggested by the American College of Cardiology and American Heart Association (ACC/AHA) that patients receiving chemotherapy can be considered to represent the A group of heart failure. Cardiomyopathy is reported more often as reversible, but in some cases it is followed by a serious fulminant heart failure and fatal outcome.…”

Section: Discussionmentioning

confidence: 99%

“…Cardiomyopathy is reported more often as reversible, but in some cases it is followed by a serious fulminant heart failure and fatal outcome. 18 It was suggested by the American College of Cardiology and American Heart Association (ACC/AHA) that patients receiving chemotherapy can be considered to represent the A group of heart failure. 19 The most clinically evident cardiotoxicity and the best recognized is the adverse effect of anthracyclines.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Heart Rate Variability and Heart Rate Turbulence in Patients with Hematologic Malignancies Subjected to High‐Dose Chemotherapy in the Course of Hematopoietic Stem Cell Transplantation

Poręba

Gać

et al. 2013

Noninvasive Electrocardiol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Heart Rate Variability and Heart Rate Turbulence in Patients with Hematologic Malignancies Subjected to High‐Dose Chemotherapy in the Course of Hematopoietic Stem Cell Transplantation

Poręba

Gać

et al. 2013

Noninvasive Electrocardiol

View full text Add to dashboard Cite

show abstract

“…A micro-voltage with sinus tachycardia is commonly observed as well as increased serum levels of troponin Ic. 4,5,7 Echocardiography constantly reveals severe biventricular failure and global hypokinesia. Pericardial effusion can be observed.…”

mentioning

confidence: 99%

Acute and fatal cardiotoxicity following high-dose cyclophosphamide in a patient undergoing autologous stem cell transplantation for systemic sclerosis despite satisfactory cardiopulmonary screening

Murray

Marcellin

et al. 2017

Bone Marrow Transplant

View full text Add to dashboard Cite

Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk

Misra

Shenoy

2016

Rheumatol Int

View full text Add to dashboard Cite

Cardiac involvement is common in primary systemic vasculitides and may be due to direct effect of the disease on the heart or due to therapy. We shall review involvement of the heart in the various forms of primary systemic vasculitis. Among anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), eosinophilic granulomatosis with polyangiitis most commonly involves the heart. Involvement of the heart confers poorer prognosis in AAV, which is also complicated by increased risk of cardiovascular events. Kawasaki's disease (KD) is the most common form of medium-vessel vasculitis to affect the heart, with coronary artery aneurysms being the most common manifestation. These predispose patients with KD to develop premature ischemic heart disease. Takayasu's arteritis is the most common large-vessel vasculitis to involve the heart and can result in aortic incompetence, myocarditis, or coronary heart disease. Involvement of the heart in Behcet's disease is usually in the form of intracardiac mass lesions, thrombosis, or endomyocardial fibrosis. Drugs used in the treatment of systemic vasculitis influence the risk of developing cardiovascular events. Corticosteroid therapy has been shown to increase the risk of myocardial infarction, whereas methotrexate, azathioprine, mycophenolate mofetil, rituximab, and anti-tumor necrosis alpha agents favorably modulate the risk of cardiovascular events, predominantly by dampening systemic inflammation. Awareness of cardiac involvement in vasculitis and accelerated cardiovascular risk in these patients should help clinicians to maximize the modulation of modifiable risk factors for heart disease in these individuals.

show abstract

Irreversible End‐Stage Cardiomyopathy Following a Single Dose of Cyclophosphamide

Cited by 5 publications

References 10 publications

Heart Rate Variability and Heart Rate Turbulence in Patients with Hematologic Malignancies Subjected to High‐Dose Chemotherapy in the Course of Hematopoietic Stem Cell Transplantation

Heart Rate Variability and Heart Rate Turbulence in Patients with Hematologic Malignancies Subjected to High‐Dose Chemotherapy in the Course of Hematopoietic Stem Cell Transplantation

Acute and fatal cardiotoxicity following high-dose cyclophosphamide in a patient undergoing autologous stem cell transplantation for systemic sclerosis despite satisfactory cardiopulmonary screening

Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk

Contact Info

Product

Resources

About